Treatment options in heparin-induced thrombocytopenia

Current Opinion in Hematology

Volumn 17, Issue 5, 2010, Pages 424-431

  Hook, Karen M ^a   Abrams, Charles S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

argatroban; factor IIa inhibitors; factor Xa inhibitors; heparin induced thrombocytopenia; lepirudin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; BMS 562247 01; DABIGATRAN; DABIGATRAN ETEXILATE; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN A; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ANAPHYLAXIS; BLEEDING; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; PRIORITY JOURNAL; REVIEW; STROKE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; POLYSACCHARIDES; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 77955923964     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833c07a7     Document Type: Review

References (126)

1. Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin N Am 2007; 21:589-607.
2. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocyto-penia. Am J Med 1996; 101:502-507.
3. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355:809-817.
4. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101:2955-2959.
5. Spencer FA. Heparin-induced thrombocytopenia: patient profiles and clinical manifestations. J Thromb Thrombolysis 2000; 10:21-25.
6. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68:95-96.
7. Greinacher A, Potzsch P, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71:247-251.
8. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000; 96:182-187.
9. Hughes M, Hayward CPM, Warkentin TE, et al. Morphological analysis of microparticle generation in Heparin-Induced Thrombocytopenia. Blood 2000; 96:188-194.
10. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived micro-particles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84:3691-3699.
11. Dager WE, Dougherty JA, Nguyen PH, et al. Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 2007; 27:564-587.
12. Warkentin TE, Sheppard JI, Siguoin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108:2937-2941.
13. Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010; 115:1797-1803.
14. Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006; 129:1407-1416.
15. Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2008; 34:86-96.
16. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100:535-540.
17. Kodityal S, Manhas AH, Udden M, Rice L Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures. Eur J Haematol 2003; 71:109-113.
18. Crespo EM, Oliveira GBF, Honeycutt EF, et al. Evaluation and management of thrombocytopenia in Heparin-Induced Thrombocytopenia in hospitalized patients: the complications after thrombocytopenia caused by heparin [CATCH] registry. Am Heart J 2009; 157:651-657.
19. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121:533-555.
20. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518-2524.
21. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost 2005; 94:132-135.
22. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and Prevention of Heparin-Induced Thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guideline (8th edition). Chest 2008; 133:340S-380S.
23. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
24. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344:1286-1292.
25. Warkentin TE, Sheppard JI. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 2006; 20:259-272.
26. Greinacher A, Michels I, Kiefel V, et al. A rapid and sensitive test for diagnosing heparin-induced thrombocytopenia. Thromb Haemost 1991; 66:734-736.
27. Alving BM. How I treat heparin-induced thrombocytopenia. Blood 2003; 101:31-37.
28. Leo A, Winteroll S. Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants. Clin Diagn Lab Immunol 2003; 10:731-740.
29. Ahmed I, Majeed A, Powell R. Heparin-induced thrombocytopenia: diagnosis and management update. Postgrad Med J 2007; 83:575-582.
30. Hassel K. Heparin-induced thrombocytopenia: diagnosis and management. Thromb Res 2008; 123:S16-S21.
31. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for Heparin-Induced Thrombocytopenia. Am J Med 1999; 106:629-635.
32. Argatroban [Product Information]. Research Triangle Park [NC], USA. Available from: URL: Http://us.gsk.com/products/asets/us-argatroban.pdf, accessed March 13, 2010.
33. Lepirudin (Refludan) [Product Information]. Wayne [NJ], USA. Available from: URL: http://www.drugs.com/pro/refludan.html, accessed March 13, 2010.
34. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003; 110:73-82.
35. Curzio KM, Cheng-Lai A, Kheyfets V, et al. A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience. J Thromb Thrombolysis 2009; 28:117-123.
36. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 1999; 99:73-80.
37. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100:587-593.
38. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Hemost 2005; 3:2428-2436.
39. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96:846-851.
40. Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 2006; 108:1492-1496.
41. Menajovsky LB. Heparin-induced thrombocytopenia: clinical manifestations and management strategies. Am J Med 2005; 118:21S-30S.
42. Linkins LA, Warkentin TE. The approach to heparin-induced thrombocytopenia. Semin Respir Crit Care Med 2008; 29:66-74.
43. Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96:2373-2378.
44. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 108:2062-2065.
45. Huhle G, Hoffman U, Song X, et al. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999; 106:195-201.
46. Linnemann B, Greinacher A, Lindhoff-Last E. Alteration of pharmacokinetics of lepirudin caused by antilepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease. Vasa 2010; 1:103-107.
47. Huhle G, Hoffman U, Hoffman I, et al. A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study. Thromb Res 2000; 99:325-334.
48. Andreescu ACM, Cushman M, Hammond JM, Wood ME. Trousseau's Syndrome treated with long-term subcutaneous lepirudin (case report and review of the literature). J Thromb Thrombolysis 2001; 11:33-37.
49. Mehta R, Golichowski A. Treatment of heparin induced thrombocytopenia and thrombosis during the first trimester of pregnancy. J Thromb Haemost 2004; 2:1665-1666.
50. Huhle G, Geberth M, Hoffmann U, et al. Management of heparin-induced thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest 2000; 49:67-69.
51. Harenberg J, Jorg I, Bayerl C, Fiehn C. Treatment of a woman with lupus pernio, thrombosis, and cutaneous intolerance to heparins using lepirudin during pregnancy. Lupus 2005; 14:411-413.
52. Tardy-Poncet B, Charier D, Diconne E. Extremely low doses of lepirudin in a patient with heparin-induced thrombocytopenia, high bleeding risk, and renal insufficiency [correspondence]. Br J Haematol 2009; 146:456-464.
53. Tschudi M, Lammle B, Alberio L Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. Blood 2009; 113:2402-2409.
54. Tardy B, Lecompte T, Boehlen, et al. GEHT-HIT study group. Blood 2006; 108:1492-1496.
55. Lewis BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cath Cardiovasc Interv 2002; 57:177-184.
56. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843.
57. Lewis BE, Wallis DE, LeyaF, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163:1849-1856.
58. Jang IK, Lewis BE, Matthai WH, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J Thromb Thrombolysis 2004; 18:31-37.
59. Hursting MJ, Jang IK. Impact of renal function on argatroban therapy during percutaneous coronary intervention. J Thromb Thrombolysis 2010; 29:1-7.
60. Koster A, Hentschel T, Groman T, et al. Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. J Thorac Cardiovasc Surg 2007; 133:1376-1377.
61. Link A, Girndt M, Selejan S, et al. Argatroban for anticoagulation in con-tinuous renal replacement therapy. Crit Care Med 2009; 37:105-110.
62. Godier A, Flaujac C, Horellou MH, et al. Argatroban and renal replacement therapy in a morbidly obese patient with heparin-induced thrombocytopenia: a case report [letter]. Thromb Res 2010 [Epub ahead of print] doi: 10.101 6/j.thromres.2009.12.018.
63. Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dialysis 2009; 22:141-145.
64. Smythe MA, Koerber JM, Forsyth L, et al. Argatroban dosage requirements and outcomes in intensive care versus nonintensive care patients. Pharma cotherapy 2009; 29:1073-1081.
65. Ansara AJ, Arif S, Warhurst RD. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2009; 43:9-18.
66. Danaparoid (Orgaran) [Product Information]. Whitehouse Station (NJ), USA. Available from: URL: http://www.merck.com/mmpe/lexicomp/danaparoid. html, accessed March 13, 2010.
67. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10171). Thromb Haemost 1993; 70:554-561.
68. Chong BH, Ismail F, Cade J, et al. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73:1592-1596.
69. Chong BH, Gallus AS, Cade JF, et al. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. Thromb Haemost 2001; 86:1170-1175.
70. Krauel K, Furll B, Warkentin TE. Heparin-induced thrombocytopenia: ther apeutic concentrations of danaparoid, unlike fondaparinux and direct throm bin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 2008; 6:2160-2167.
71. Blackmer AB, Oertel MD, Valgus JM. Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues. Ann Pharmac other 2009; 43:1636-1646.
72. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127:804-812.
73. Warkentin TE, Sikov WM, Lillicrap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am J Hematol 1999; 62:44-48.
74. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004; 164:66-70.
75. Hursting MJ, Soffer J. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombo cytopenia. Drug Saf 2009; 32:203-218.
76. Bivalirudin (Angiomax) [Product Information]. Parsippany [NJ], USA. Available from: URL: http://www.angiomax.com/Files/SalesAidRef/PI.pdf, accessed March 13, 2010.
77. Arixtra (fondaparinux) [Product Information]. Research Triangle Park [NC], USA. Available from: URL: http://us.gsk.com/products/assets/us-arixtra. pdf, accessed March 13, 2010.
78. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99:830-839.
79. Czosnowski QA, Finks SW, Rogers KC. Bivalirudin for patients with heparin-induced thrombocytopenia undergoing cardiovascular surgery. Ann Pharmacother 2008; 42:1304-1309.
80. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143:847-853.
81. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention [the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-1 trial]. Am J Cardiol 2004; 93:1092-1096.
82. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. (REPLACE)-2 trial. J Am Med Assoc 2003; 289:853-863.
83. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003; 15:611-616.
84. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203-2216.
85. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007; 83:572-577.
86. Dyke CM, Aldea G, Koster A, et al. Off-pump coronary bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007; 84:836-840.
87. Kiser TH, Burch JC, Klem PM. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2008; 28:1115-1124.
88. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006; 26:452-460.
89. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20:318-329.
90. Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 2004; 17:105-125.
91. Berkowitz SD. Bivalirudin in heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) patients [abstract]. Blood 1999; 94 (Suppl 1):101b.
92. Francis JL, Drexler A, Gwyn G, Moroose R. Successful use of bivalirudin in the treatment of patients suspected, or at risk of, heparin-induced thrombo-cytopenia [abstract]. Blood (ASH Annual Meeting Abstracts) 2004; 104:4077.
93. Ramirez LM, Carman TL, Begelman SM, et al. Bivalirudin in patients with HIT or clinically suspected HIT [abstract]. Blood (ASH Annual Meeting Abstracts) 2005; 106:918.
94. Dang CH, Durkalski VL, Nappi JM. Evaluation and treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2006; 26:461-468.
95. Warkentin TE, Cook RJ, Marder VJ. Antiplatelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fonda-parinux or enoxaparin. Blood 2005; 106:3791-3796.
96. Papadpoulous S, Flynn JD, Lewis DA. Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmacotherapy 2007; 27:921-926.
97. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105:139-144.
98. Ratuapli SK, Bobba B, Zafar H. Heparin-induced thrombocytopenia in a patient treated with fondaparinux. Clin Adv Hematol Oncol 2010; 8:61-62.
99. Alsaleh KA, Al-Nasser SMA, Bates SM, et al. Delayed-onset HIT caused by low-molecular weight heparin manifesting during fondaparinux prophylaxis. Am J Hematol 2008; 83:876-878.
100. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99:779-781.
101. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux [letter]. N Engl J Med 2007; 356:2653-2655.
102. Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 2006; 40:1383-1387.
103. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin induced thrombocytopenia. Thromb Haemost 2008; 99:208-214.
104. Grouzi E, Kyraikou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Haemost 2009 [Epub ahead of print] doi: 10.1177/ 1076029609347900.
105. Mazzolai L, Hohlfeld P, Spertini F, et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108:1569-1570.
106. Filis K, Lagoudianakis EE, Pappas A, et al. Heparin-induced thrombocyto-penia and phlegmasia cerulean dolens of the upper limb successfully treated with fondaparinux. Acta Haematol 2008; 120:190-191.
107. Seldrum S, Lambert M, Hainaut P. Heparin-induced thrombocytopenia successfully treated with fondaparinux. Acta Clin Belg 2009; 64:144-146.
108. Spyropoulos AC, Magnuson S, Koh SK. The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thrombocytopenia and thrombosis caused by heparin flushes. Therapeut Clin Risk Manag 2008; 4:653-657.
109. Kovacs MJ. Successful treatment of heparin induced thrombocytopenia [HIT] with fondaparinux. Thromb Haemost 2005; 93:999-1000.
110. Warkentin TE. Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT): bridging the River Coumarin [editorial]. Thromb Haemost 2008; 99:2-3.
111. Wester JP, Leyte A, Oudemans-van Straaten HM, et al. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill. Neth J Med 2007; 65:101-108.
112. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115:15-20.
113. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47:47-59.
114. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 28:1354-1373.
115. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, noninferiority trial. Lancet 2007; 370:949-956.
116. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5:2178-2185.
117. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24:1-9.
118. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342-2352.
119. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
120. Haas S. Rivaroxaban: an oral, direct factor Xa inhibitor: lessons from a broad clinical study programme. Eur J Haematol 2009; 82:339-349.
121. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2675-2775.
122. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 2008; 372:31-39.
123. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2276-2286.
124. TurpieAG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373:1673-1680.
125. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-1). N Engl J Med 2009; 361:594-604.
126. Lassen MR, Raskob GE, Gallus A, et al. Apixapan versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet 2010; 375:807-815.